Status:
WITHDRAWN
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
Lead Sponsor:
University of California, San Francisco
Conditions:
Infection
Transplant;Failure,Kidney
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Infections are common and associated with poor outcomes as well as high financial costs after kidney transplantation. Identifying and implementing strategies to reduce infections after kidney transpla...
Eligibility Criteria
Inclusion
- Adult transplant recipients ≥18 years of age who have a functional allograft and have undergone kidney transplantation between six months and two years prior to study enrollment
- Receiving mycophenolate mofetil for maintenance transplant immunosuppression at the time of the screening visit
Exclusion
- Evidence of rejection on routine six month post-transplant biopsy
- Prior intolerance to mycophenolate mofetil necessitating drug discontinuation
- Are or are planning to become pregnant, due to inability to take mycophenolate
- Are marginally housed, due to concerns regarding routine follow-up
- Are actively participating in a different interventional trial that may affect immunosuppression dosing
- Are unwilling to consent to participate
- Institutionalized individuals or prisoners
- Are actively abusing illicit drugs or alcohol
- Have a history of poor or doubtful compliance (e.g., frequently missed appointments)
- Have cognitive impairment prohibiting participation in the study
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04473924
Start Date
July 1 2022
End Date
May 1 2023
Last Update
May 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143